KHK4951 clinical trials
Also written KHK4951.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses KHK4951 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KHK4951
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 2 |
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses KHK4951 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaActive, not recruitingPhase 2Kyowa Kirin Co., Ltd.NCT06116916Written as KHK4951How we know
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationCompletedPhase 2Kyowa Kirin Co., Ltd.NCT06116890Written as KHK4951How we know
- A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationTerminatedPhase 1Kyowa Kirin Co., Ltd.NCT04594681Written as KHK4951How we know